EA201171207A1 - Биодоступные композиции аморфного альфа-(n-сульфонамидо)ацетамидного соединения - Google Patents

Биодоступные композиции аморфного альфа-(n-сульфонамидо)ацетамидного соединения

Info

Publication number
EA201171207A1
EA201171207A1 EA201171207A EA201171207A EA201171207A1 EA 201171207 A1 EA201171207 A1 EA 201171207A1 EA 201171207 A EA201171207 A EA 201171207A EA 201171207 A EA201171207 A EA 201171207A EA 201171207 A1 EA201171207 A1 EA 201171207A1
Authority
EA
Eurasian Patent Office
Prior art keywords
sulfonamido
bio
acetamide compound
compositions
amorphous alpha
Prior art date
Application number
EA201171207A
Other languages
English (en)
Inventor
Руйлинг Ф. Хартли
Раджа М. Хаддадин
Фэн Цянь
Original Assignee
Бристол-Маерс Сквибб Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бристол-Маерс Сквибб Компани filed Critical Бристол-Маерс Сквибб Компани
Publication of EA201171207A1 publication Critical patent/EA201171207A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Предложены для таблетирования композиции в форме аморфной твердой дисперсии, содержащие (2R)-2-[[(4-хлорфенил)сульфонил][[2-фтор-4-(1,2,4-оксадиазол-3-ил)фенил]метил]амино]-5,5,5-трифторпентанамид и поливинилпирролидонвинилацетат или гидроксипропилметилцеллюлозы ацетата сукцинат.
EA201171207A 2009-04-14 2010-04-12 Биодоступные композиции аморфного альфа-(n-сульфонамидо)ацетамидного соединения EA201171207A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16906609P 2009-04-14 2009-04-14
PCT/US2010/030679 WO2010120662A2 (en) 2009-04-14 2010-04-12 Bioavailable compositions of amorphous alpha-(n-sulfonamido)acetamide compound

Publications (1)

Publication Number Publication Date
EA201171207A1 true EA201171207A1 (ru) 2012-03-30

Family

ID=42664672

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201171207A EA201171207A1 (ru) 2009-04-14 2010-04-12 Биодоступные композиции аморфного альфа-(n-сульфонамидо)ацетамидного соединения

Country Status (21)

Country Link
US (1) US20100261768A1 (ru)
EP (1) EP2419086B1 (ru)
JP (1) JP2012524090A (ru)
KR (1) KR20120027142A (ru)
CN (1) CN102387788B (ru)
AR (1) AR076306A1 (ru)
AU (1) AU2010236701A1 (ru)
BR (1) BRPI1012523A2 (ru)
CA (1) CA2758709A1 (ru)
DK (1) DK2419086T3 (ru)
EA (1) EA201171207A1 (ru)
ES (1) ES2426403T3 (ru)
HR (1) HRP20130807T1 (ru)
MX (1) MX2011010513A (ru)
NZ (1) NZ595411A (ru)
PL (1) PL2419086T3 (ru)
PT (1) PT2419086E (ru)
SI (1) SI2419086T1 (ru)
SM (1) SMT201300106B (ru)
TW (1) TW201043269A (ru)
WO (1) WO2010120662A2 (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS51155B (sr) 2001-12-20 2010-10-31 Bristol-Myers Squibb Company DERIVATI α -(N-SULFONAMIDO)ACETAMIDA KAO INHIBITORI β -AMILOIDA
US8044077B2 (en) 2009-03-19 2011-10-25 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production
US7977362B2 (en) 2009-03-20 2011-07-12 Bristol-Myers Squibb Company Alpha-(N-benzenesulfonamido)cycloalkyl derivatives
US8252821B2 (en) 2009-04-14 2012-08-28 Bristol-Myers Squibb Company Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound
US9095585B2 (en) * 2011-07-21 2015-08-04 Bristol-Myers Squibb Company Bioavailable compositions of amorphous piperidinyl compounds
US20150045353A1 (en) * 2013-08-09 2015-02-12 Neurogenetic Pharmaceuticals, Inc. Formulations containing gamma secretase modulators, methods for preparation and delivery thereof
TWI765410B (zh) 2014-08-08 2022-05-21 日商中外製藥股份有限公司 ４環性化合物的非晶質體的用途

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3999007A (en) * 1975-10-09 1976-12-21 Carl Joseph Crane Aircraft visual approach/landing reproducer device and system
US5136301A (en) * 1989-08-30 1992-08-04 Rockwell International Corporation Primary flight display system having a vertical linear altimeter
US5274094A (en) * 1990-08-15 1993-12-28 British Bio-Technology Limited Production of heterobicyclic containing benzene sulfonamides
GB9202791D0 (en) * 1992-02-11 1992-03-25 British Bio Technology Compounds
DE69606804T2 (de) * 1995-06-20 2000-06-15 Honeywell, Inc. Integriertes System zur Grundkollisionsvermeidung
NZ321293A (en) * 1995-11-17 2001-04-27 Warner Lambert Co Sulfonamide inhibitors of matrix metalloproteinases
EP1093564B1 (en) * 1998-07-06 2006-11-08 Honeywell International Inc. Aircraft position validation using radar and digital terrain elevation database
US6313123B1 (en) * 1999-01-27 2001-11-06 American Cyanamid Company Acetylenic sulfonamide thiol tace inhibitors
US6570531B1 (en) * 2000-04-27 2003-05-27 Rockwell Collins, Inc. Satellite navigation receiver designed for compatibility with aircraft automatic landing systems
US6483454B1 (en) * 2000-11-28 2002-11-19 Bae Systems Aerospace Inc. Close formation aircraft collision avoidance
RS51155B (sr) * 2001-12-20 2010-10-31 Bristol-Myers Squibb Company DERIVATI α -(N-SULFONAMIDO)ACETAMIDA KAO INHIBITORI β -AMILOIDA
NZ542468A (en) * 2003-03-31 2009-01-31 Wyeth Corp Fluoro- and trifluoroalkyl-containing heterocyclic sulfonamide inhibitors of beta amyloid production and derivatives thereof
US20050048112A1 (en) * 2003-08-28 2005-03-03 Jorg Breitenbach Solid pharmaceutical dosage form
FR2870605B1 (fr) * 2004-05-18 2010-10-08 Airbus France Procede et dispositif de guidage automatique d'un aeronef, pour un vol au moins en partie a basse altitude
FR2880456B1 (fr) * 2005-01-03 2007-02-23 Airbus France Sas Procede et dispositif d'alerte sonore lors de la desactivation d'un pilote automatique d'un aeronef
FR2886439B1 (fr) * 2005-05-24 2010-11-05 Eurocopter France Procede et dispositif d'aide au pilotage d'un aeronef a basse altitude
AU2006340003A1 (en) * 2005-11-09 2007-09-20 Novartis Ag Process for making pharmaceutical compositions with a transient plasticizer
FR2897448B1 (fr) * 2006-02-14 2008-03-14 Airbus France Sas Procede et systeme d'aide au pilotage d'un aeronef.
AR059517A1 (es) * 2006-02-17 2008-04-09 Wyeth Corp N- sulfonilacion selectiva de alcoholes sustituidos con 2- aminotrifluoralquilo
BRPI0707741A2 (pt) * 2006-02-17 2011-05-10 Wyeth Corp mÉtodos para preparar um amino Álcool, ou sal do mesmo, e um Álcool substituÍdo por sulfonamida
RS20090406A (en) * 2006-03-20 2010-12-31 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions
EP2001498A4 (en) * 2006-03-20 2013-01-23 Vertex Pharma PHARMACEUTICAL COMPOSITIONS
FR2911988B1 (fr) * 2007-01-26 2016-03-25 Airbus France Procede et dispositif pour determiner une hauteur maximale de stabilisation lors de la phase finale de vol d'un avion
US8084477B2 (en) * 2007-10-31 2011-12-27 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production

Also Published As

Publication number Publication date
KR20120027142A (ko) 2012-03-21
TW201043269A (en) 2010-12-16
MX2011010513A (es) 2011-11-29
SMT201300106B (it) 2013-11-08
PT2419086E (pt) 2013-09-04
WO2010120662A2 (en) 2010-10-21
AR076306A1 (es) 2011-06-01
EP2419086B1 (en) 2013-06-26
EP2419086A2 (en) 2012-02-22
CN102387788A (zh) 2012-03-21
NZ595411A (en) 2013-02-22
SI2419086T1 (sl) 2013-10-30
PL2419086T3 (pl) 2013-11-29
US20100261768A1 (en) 2010-10-14
WO2010120662A3 (en) 2011-09-15
HRP20130807T1 (hr) 2013-09-30
CN102387788B (zh) 2013-07-10
AU2010236701A1 (en) 2011-10-20
JP2012524090A (ja) 2012-10-11
ES2426403T3 (es) 2013-10-23
CA2758709A1 (en) 2010-10-21
DK2419086T3 (da) 2013-09-30
BRPI1012523A2 (pt) 2016-03-29

Similar Documents

Publication Publication Date Title
EA201171207A1 (ru) Биодоступные композиции аморфного альфа-(n-сульфонамидо)ацетамидного соединения
EA201001680A1 (ru) Соединения бензолсульфонамидтиазола и оксазола
NO20081618L (no) Anvendelse av proteiner som en antiskumdannende komponent i drivstoff
EA201270625A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
DK1720550T3 (da) Derivater af piperidinylalkylcarbamater, fremstilling heraf samt anvendelse heraf som inhibitorer for FAAH enzym
EA201290255A1 (ru) Способы и композиции для лечения рака
NO20083630L (no) Nye pyridinderivater
DK1874306T3 (da) Sammensætninger af en oralt aktiv 1,2,4-oxadiazol til nonsens-mutationssuppressionsterapi
BRPI0615900A2 (pt) granulados de enzima, uso de um granulado de enzima, e, ração
MY154909A (en) Novel thiophene derivatives
EA200970211A1 (ru) Применение производных азабициклогексана
DK1957656T3 (da) Fermentativ fremstilling af lysin
BRPI0921699A2 (pt) complexo antioxidante, composicoes cosmeticas e farmaceutica contendo o referido complexo e uso deste complexo
DK2073805T3 (da) Fremgangsmåder til dosering af en oralt aktiv 1,2,4-oxadiazol til terapi for suppression af nonsens-mutation
EA201000545A1 (ru) Композиция зиботентана, содержащая маннит и/или микрокристаллическую целлюлозу
EA201170680A1 (ru) Ингибиторы акт и p70 s6-киназы
EA200801414A1 (ru) Кальцилитические соединения
AR055755A1 (es) Derivado de bencimidazol, procesos de obtencion, composiciones farmaceuticas y usos.
EA200900942A1 (ru) Гербицидная композиция
BRPI0912551A2 (pt) compostos para tingimento de queratina, composições para tingimento de queratina contendo os ditos compopstos, e uso dos mesmos
DK1848394T3 (da) Fremstilling af doseringsformer af smeltemasser, der indeholder aktive bestanddele
CL2008002058A1 (es) Metodo para la preparacion de trifluoralquil-fenil-sulfonamidas y de sulfonamidas heterociclicas usando n-trifluoroacteilmorfolina; su metodo de preparacion y su uso.
HK1118276A1 (en) Ethanolamine salt of n-(3-methoxy-5-methylpyrazin-2yl)-2-(4-[1,3,4- oxadiazole-2-yl]phenyl)pyridine-3-sulphonamide
WO2006122012A3 (en) Polymorphic forms of (s)- tetrahydrofuran-3-yl-3-(3-(3-methoxy-4-(oxazol-5-yl) phenyl) ureido) benzylcarbamate
DE602005002304D1 (de) Verwendung von 3-(Methoxymethyl)-2-Pentylcyclopenta-Derivaten in Riechstoffkompositionen